Physician profile
Brian R Stephens
NPI 1144219825
$6,962.93
in general payments reported to CMS, 2019-2025
31 companies · $1,720 in 2025
The $1,720 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $302 · 2021: $587 · 2022: $1,681 · 2023: $582 · 2024: $1,048 · 2025: $1,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,342 · Education: $7.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,342.31 |
| Education | $7.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $931.32 | 2022 | |
| Alcon Vision LLC | $665.15 | 2019-2025 | Tryptyr, Clareon Panoptix Pro, Rocklatan |
| Abbvie INC. | $629.29 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Novartis Pharmaceuticals Corporation | $538.30 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $515.33 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $479.70 | 2019-2025 | Cequa |
| Glaukos Corporation | $392.32 | 2024-2025 | Idosetr |
| Tarsus Pharmaceuticals, INC. | $352.00 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $325.87 | 2019-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $315.36 | 2019-2022 | |
| Allergan, INC. | $312.21 | 2019-2021 | |
| Harrow Eye, LLC | $204.30 | 2024-2025 | Vevye, Verkazia, Flarex |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $167.46 | 2019-2021 | |
| Oyster Point Pharma, INC. | $150.42 | 2022-2025 | Tyrvaya, Ryzumvi |
| Mallinckrodt Enterprises LLC | $145.69 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $125.85 | 2021-2025 | Acthar |
| Sight Sciences, INC. | $91.01 | 2021-2023 | Omni Surgical System |
| Regeneron Healthcare Solutions, INC. | $90.98 | 2024-2025 | Eylea Hd, Eylea |
| Shire North American Group INC | $83.89 | 2019 | |
| Astellas Pharma US INC | $78.77 | 2025 | Izervay |
| Amgen INC. | $64.44 | 2024-2025 | Tepezza |
| Tearlab Corp | $46.22 | 2023 | Tearlab Osmolarity System |
| Biotissue Holdings INC. | $44.13 | 2023-2024 | |
| Thea Pharma INC. | $41.25 | 2025 | Iyuzeh |
| Genentech USA, INC. | $34.35 | 2025 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $32.99 | 2019 | |
| Apellis Pharmaceuticals, INC. | $26.34 | 2025 | Syfovre |
| Horizon Therapeutics Plc | $22.74 | 2022 | |
| Alimera Sciences, INC. | $22.63 | 2021 | |
| Lumenis, INC | $19.32 | 2021 | |
| Rxsight INC | $13.30 | 2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.